A 43-Year-Old with Node-Positive ER-Positive Breast Cancer and a High Recurrence Score
43-year-old premenopausal woman undergoes lumpectomy and sentinel node biopsy for a 2.4 cm grade 2 invasive ductal carcinoma. One of three sentinel nodes contains a 4 mm metastasis. The tumor is ER 90%, PR 70%, HER2-negative, Ki-67 25%. A 21-gene recurrence score is 28. She has no family history and no pathogenic BRCA variant. She is married, has no children, and has a low anti-Müllerian hormone level. She wants to know whether chemotherapy is truly necessary, whether ovarian suppression is needed, and whether she can still preserve fertility before starting treatment. She is anxious about early menopause and has read that some women omit chemotherapy when the recurrence score is below 30. She asks for a clear plan that addresses both cancer outcome and future fertility.
1. How do you interpret the 21-gene recurrence score of 28 in a 43-year-old, and what systemic therapy do you recommend?
Read the worked answer
The recurrence score must be interpreted with age. In TAILORx, women aged 50 or younger with a score of 26–30 derived a clinically meaningful benefit from adding chemotherapy to endocrine therapy, whereas older women in that range did not. At 43 with a score of 28 and node-positive disease, she is not a candidate for chemotherapy omission based on the recurrence score alone.
I recommend sequential anthracycline-taxane chemotherapy or a taxane-cyclophosphamide regimen, followed by endocrine therapy. Because she is premenopausal and high-risk, ovarian suppression plus an aromatase inhibitor (or tamoxifen if an AI is not tolerated) is appropriate; SOFT and TEXT support ovarian suppression in high-risk premenopausal disease. The exact endocrine choice should account for her bone health, menopausal symptoms, and preference.
If she were to decline chemotherapy, I would document the discussion and still recommend ovarian suppression plus endocrine therapy, but I would explain that this is a weaker option for a score of 28 at her age. I would not use the score as a reason to avoid chemotherapy simply because it is below 30; age is the decisive modifier here.
2. She asks about ovarian suppression versus tamoxifen alone and whether she can preserve fertility. Outline your approach.
Read the worked answer
Ovarian suppression is not just another way to give tamoxifen; it is a separate treatment decision. In high-risk premenopausal disease, adding ovarian suppression to tamoxifen or an aromatase inhibitor improves outcomes, especially in women under 35 and those who remain premenopausal after chemotherapy. Given her age and node-positive disease, I would recommend ovarian suppression plus an aromatase inhibitor, with tamoxifen as an alternative if AI toxicity is problematic.
Fertility must be addressed before chemotherapy:
- Refer urgently to reproductive endocrinology. Random-start controlled ovarian stimulation can be performed without waiting for a specific cycle day, and embryo or oocyte cryopreservation is the most established method.
- Explain that chemotherapy may reduce ovarian reserve and that her low AMH already suggests limited reserve.
- A GnRH agonist during chemotherapy is controversial and should not replace fertility preservation; it may be offered as an adjunct after shared decision-making.
- Do not start endocrine therapy until fertility preservation is complete. If she becomes pregnant later, endocrine therapy must be interrupted; the POSITIVE trial supports discussing temporary interruption after 18–30 months in selected women, but this is a shared decision.
3. What is your surveillance plan and advice on timing of pregnancy after completion of therapy?
Read the worked answer
Surveillance should focus on detecting recurrence and managing endocrine therapy toxicity. I would see her every 3–6 months for history and examination for the first three years, then every 6–12 months, with annual bilateral mammography. I would not order routine tumor markers, bone scans, or CT scans in the absence of symptoms because they do not improve survival and add false positives.
Pregnancy timing:
- Advise avoiding pregnancy during chemotherapy and for at least the first 1–2 years after diagnosis, when recurrence risk is highest.
- Standard endocrine therapy lasts 5–10 years. If she wishes to conceive, discuss temporary interruption after at least 18–30 months of endocrine therapy, ideally with a multidisciplinary team and after documenting her recurrence risk. The POSITIVE trial suggests this can be considered in selected patients, but it is not risk-free.
- Refer for high-risk obstetric care when she conceives and resume endocrine therapy after pregnancy and breastfeeding.
- Reassure her that a prior breast cancer diagnosis is not an absolute contraindication to pregnancy, but the decision must balance recurrence risk, endocrine therapy duration, and her fertility trajectory.